# Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

> **NCT06451211** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 53 (estimated)

## Conditions studied

- Stomach Neoplasms
- Gastric Cancer
- Linitis Plastica of Stomach

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Oxaliplatin
- **DRUG:** S-1
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06451211
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-17
- **Primary completion:** 2024-11
- **Final completion:** 2027-11
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06451211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06451211, "Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06451211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*